Thymic Health Emerges as Key Predictor of Cancer Immunotherapy Success, New Research Shows

A groundbreaking body of research presented at the ESMO Congress 2025 has unveiled that thymic health—the condition of the thymus gland—may play a critical role in predicting how well cancer patients respond to immunotherapy, regardless of cancer type. This discovery, using artificial intelligence (AI) analysis of routine CT scans and corroborated by extensive blood-based studies, introduces a novel approach that could transform patient selection and treatment strategies in oncology.​

What Is the Thymus and Why Does It Matter?

The thymus is a gland located behind the breastbone, responsible for the maturation of T cells, the immune system’s key fighters against infection and cancer. While it is well-known that the thymus shrinks and becomes less active with age, until now, its relevance in adult cancer patients receiving immunotherapy has remained largely unexplored.​

Key Study Findings: Thymic Health Linked to Immunotherapy Outcomes

Researchers led by Dr. Simon Bernatz at Mass General Brigham, Boston, analyzed chest CT scans from 3,476 patients treated with immune checkpoint inhibitors, a common form of cancer immunotherapy. Using deep learning, they created a scoring system quantifying thymic size, shape, and structure. They found that:

• Patients with higher thymic health enjoyed a 37% lower risk of cancer progression and a 44% lower risk of death when treated with immunotherapy compared to those with less healthy thymic tissue.​

• This relationship held true across a variety of cancer types, from lung to bladder to kidney cancer, suggesting thymic health may serve as a broad, “tumor-agnostic” biomarker.​

• In the HARVARD-NSCLC cohort of 1,218 non-small cell lung cancer patients, high thymic health yielded improved progression-free survival (adjusted HR 0.63; 95% CI 0.50–0.80; p<0.001) and overall survival (adjusted HR 0.56; 95% CI 0.43–0.74; p<0.001).​

Biological Mechanisms: Immune Reserves Beyond the Tumor

Blood analyses from the TRACERx study further validated the findings, revealing that individuals with better thymic health also retained higher diversity in their T-cell receptor repertoire and a larger fraction of circulating T cells. This means their immune systems may be more adaptable and robust, which is critical when leveraging immunotherapy’s mechanism of “unleashing” the body’s natural defenses.​

Expert Perspectives: Implications and Next Steps

Dr. Samra Turajlić, a leading oncologist at the Christie NHS Foundation Trust in the UK, commented that this research marks a departure from strategies solely focused on the tumor itself, advocating for biomarkers that capture the broader health of the host immune system.​

Prof. Alessandra Curioni-Fontecedro from the University of Fribourg also noted the potential of thymic assessment to fill a significant gap in patient stratification: “We have some biomarkers related to the tumor itself, but no measure of overall immune health—thymic evaluation could be very valuable in this regard”.​

Practical Implications for Patients and Clinicians

If validated in further clinical trials, routine evaluation of thymic health could become an important step in tailoring immunotherapy. Currently, most treatment decisions rely on tumor-specific markers like PD-L1 expression or tumor mutational burden, but these do not account for the patient’s general immune capacity. The ability to integrate thymic assessment, using widely available CT scans, could help doctors identify patients more likely to benefit from immunotherapy or those who may need alternative approaches.​

Limitations and Counterarguments

It’s important to recognize that the research is still new and requires validation in prospective studies and diverse patient populations. The thymus can be affected by prior chemotherapy, radiation, infections, and autoimmune diseases, which may confound results. Furthermore, the study relied on imaging proxies rather than direct measurements of thymic function, and there is currently no consensus on standardized scoring for thymic health in the clinical setting.​

Balanced View: A Step Forward, Not a Silver Bullet

While the use of host-immune biomarkers like thymic health is promising, experts caution it should be used in conjunction with established methods rather than as a standalone predictor. Cancer treatment is multi-faceted, and no single factor can capture the complexity of an individual’s biology or treatment response.​

Responsible Health Communication: What Should Patients Know?

For now, the best approach for patients is continued dialogue with their oncology team and participation in clinical trials where available. Emphasis remains on evidence-based medicine and a personalized, holistic approach to care.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References​